 |
Horizon Pharma Announces First Quarter 2012 Financial Results
May 10, 2012
|
32.3 KB |
|
| |
DEERFIELD, IL -- (Marketwire) -- 05/10/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the first quarter ended March 31, 2012.
DUEXIS®/RAYOS® Highlights
DUEXIS, the Company's proprietary single-tablet combination of ibuprofe...
|
|
Annals of the Rheumatic Diseases Publishes Pivotal Phase 3 Study Demonstrating Efficacy and Safety of RAYOS(R) (Delayed-Release Prednisone) in Combination With DMARD Therapy in Rheumatoid Arthritis Patients
May 7, 2012
|
17.7 KB |
|
| |
DEERFIELD, IL -- (Marketwire) -- 05/07/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the Annals of the Rheumatic Diseases has published results from the CAPRA-2 (Circadian Administration of Prednisone in Rheumatoid Arthritis-2) U.S. registration study, which demonstrated that patients with active rheumatoid arthritis (RA) trea...
|
|
Horizon Pharma to Present at the 11th Annual JMP Securities Research Conference
May 2, 2012
|
12.5 KB |
|
| |
DEERFIELD, IL -- (Marketwire) -- 05/02/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present at the JMP Securities Research Conference on Monday, May 14, 2012 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern time) in San Francisco, CA. Mr. Walbert will prov...
|
|
Horizon Pharma to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results on May 10, 2012
May 1, 2012
|
12.8 KB |
|
| |
DEERFIELD, IL -- (Marketwire) -- 05/01/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its first quarter 2012 financial results will be released on Thursday, May 10, 2012. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and op...
|
|
Horizon Pharma Files Patent Infringement Lawsuit Against Par Pharmaceutical, Inc. for Filing an ANDA Against DUEXIS(R)
Mar 28, 2012
|
14.1 KB |
|
| |
DEERFIELD, IL -- (Marketwire) -- 03/28/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Par Pharmaceutical, Inc. ("Par") and related to an Abbreviated New Drug Application ("ANDA") that Par filed with the U.S. Food and D...
|
|
Horizon Pharma Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 23, 2012
|
35.3 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 03/23/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today reported financial results for the fourth quarter and year ended December 31, 2011, and provided an update on recent accomplishments by the Company. The Company ended the year with cash and cash equivalents totaling $18.0 million. Subsequent to the end of t...
|
|
Horizon Pharma Appoints Gino Santini to Board of Directors
Mar 8, 2012
|
15.3 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 03/08/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the appointment of Gino Santini to the Company's Board of Directors. Mr. Santini, age 55, retired as Senior Vice President of Corporate Strategy and Business Development of Eli Lilly in December 2010, after a career with the company of more than 2...
|
|
Horizon Pharma Enters Into Exclusive Agreement With Mundipharma for Commercialization of LODOTRA(R) (Modified-Release Prednisone) in Latin America
Mar 7, 2012
|
16.0 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 03/07/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP), a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that its Swiss subsidiary and Mundipharma International Corporation Limited and Mundip...
|
|
Horizon Pharma Announces $50.8 Million Private Placement
Feb 29, 2012
|
14.7 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 02/29/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today the execution of a securities purchase agreement with a select group of institutional and accredited investors providing for a private placement financing. Upon the closing of the private financing, Horizon will receive gross proceeds of approxima...
|
|
Horizon Pharma Secures $60 Million Loan Facility
Feb 22, 2012
|
14.9 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 02/22/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that it has entered into a loan agreement with a group of lenders to provide $60 million in capital. Horizon used $22.4 million of the loan proceeds to repay the remaining obligations under its loan agreements with Oxford Finance LLC, Silicon Vall...
|
|
Horizon Pharma to Present at the Cowen and Company Health Care Conference
Feb 21, 2012
|
12.6 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 02/21/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present at the Cowen and Company 32nd Annual Health Care Conference on Monday, March 5th at 4:50p.m. Eastern Time in Boston, MA. Mr. Walbert will provide an overview of...
|
|
Horizon Receives Notice of Paragraph IV Certification Against Patents for DUEXIS(R)
Feb 16, 2012
|
14.1 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 02/16/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP), today announced that it had received a Paragraph IV Patent Certification from Par Pharmaceutical, Inc. ("Par") advising that Par has filed an Abbreviated New Drug Application ("ANDA") with the U.S. Food and Drug Administration ("FDA") for a generic version of DUE...
|
|
Horizon Pharma Modifies DUEXIS(R) Marketing Authorization Application to Include Recently Approved Manufacturing Site
Feb 13, 2012
|
62.5 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 02/13/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has modified the DUEXIS® (ibuprofen/famotidine) Marketing Authorization Application (MAA) submission to the National Procedure in the United Kingdom to include the recently approved Valeant Pharmaceuticals manufacturing site in Laval,...
|
|
Horizon Pharma to Present at the 14th Annual BIO CEO and Investor Conference
Feb 2, 2012
|
12.5 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 02/02/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, is scheduled to present at the 14th Annual BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 1:30pm Eastern Time in New York, NY. Mr. Walbert will provide an ...
|
|
Horizon Pharma Announces Launch of DUEXIS(R) (Ibuprofen/Famotidine) 800 mg/26.6 mg in the United States
Dec 5, 2011
|
64.4 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 12/05/11 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that DUEXIS® (ibuprofen/famotidine), a proprietary single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg), is now available to U.S. physicians for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthri...
|
|
Horizon Pharma Announces U.S. Food and Drug Administration Acceptance of LODOTRA(R) New Drug Application for Review for the Treatment of Rheumatoid Arthritis
Nov 29, 2011
|
18.3 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 11/29/11 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the United States Food and Drug Administration (FDA) has accepted for filing and review its New Drug Application (NDA) for LODOTRA®, a proprietary modified (delayed)-release formulation of low-dose prednisone, for the treatment of rheuma...
|
|
Horizon Pharma Reports Third Quarter 2011 Financial Results and Provides DUEXIS Launch Update
Nov 14, 2011
|
32.4 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 11/14/11 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today reported financial results for the quarter ended September 30, 2011 and provided an update on recent accomplishments and the status of the DUEXIS launch. The Company ended the third quarter with cash and cash equivalents totaling $33.0 million. Total revenu...
|
|
Horizon Pharma and Sanofi Announce FDA Approval of DUEXIS(R) Commercial Manufacturing Facility
Nov 14, 2011
|
63.6 KB |
|
| |
DEERFIELD, IL and BRIDGEWATER, NJ -- (MARKET WIRE) -- 11/14/11 --
Horizon Pharma, Inc. (NASDAQ: HZNP) and Sanofi announced today that the U.S. Food and Drug Administration (FDA) has approved the use of the sanofi-aventis Canada Inc. manufacturing site in Laval, Quebec to manufacture DUEXIS®, (ibuprofen/famotidine) a proprietary single-tab...
|
|
Horizon Pharma to Ring the NASDAQ Stock Market Closing Bell on October 24, 2011
Oct 21, 2011
|
13.4 KB |
|
| |
DEERFIELD, IL -- (MARKET WIRE) -- 10/21/11 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the Company's chairman, president and chief executive officer, Timothy P. Walbert, is scheduled to preside over the NASDAQ Closing Bell Ceremony in New York on Monday, October 24, 2011 at 4:00 p.m. ET. Horizon's common stock began trading on ...
|
|
Horizon Pharma Receives U.S. Patent Allowance for DUEXIS(R) in the United States
Oct 13, 2011
|
62.4 KB |
|
| |
NORTHBROOK, IL -- (MARKET WIRE) -- 10/13/11 --
Horizon Pharma, Inc. (NASDAQ: HZNP) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for Application Serial No. 12/324808 entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover DUEXIS®.
The Notice ...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz